- Daily Industry Report
- Posts
- Daily Industry Report - August 31
Daily Industry Report - August 31

Your summary of the Voluntary and Healthcare Industry’s most relevant and breaking news; brought to you by the Health & Voluntary Benefits Association®
Jake Velie, CPT | Robert S. Shestack, CCSS, CVBS, CFF |
New bill aims to cap out-of-pocket prescription costs
By Allison Bell – A lawmaker has brought back a bill that could please workers who are angry about what they pay out of their own pockets for prescription drugs. Rep. Hillary Scholten, D-Mich., introduced the "Fair Prescription Pricing Act of 2026" bill last week. The bill would limit copayments for patients who buy prescription drugs using an individual major medical policy, group health insurance coverage or coverage from an employer's self-insured health plan. The patient's cost-sharing for the drug would have to be less than or equal to the nationwide average of consumer purchase prices for the drug, according to the bill text. Read Full Article... (Subscription required)
HVBA Article Summary
How the cap would be calculated and applied: The proposal would set a ceiling on a patient’s prescription cost-sharing based on a nationwide average consumer purchase price derived from a survey. It would apply across common coverage types, including individual major medical policies, fully insured group coverage, and employer self-insured plans. The definition of cost-sharing is broad, encompassing deductibles, coinsurance, and copays rather than focusing on copays alone. This structure aims to prevent scenarios where insured patients pay more out of pocket than typical retail consumer prices for the same drug.
Legislative status and prior precedent: The measure was introduced by Rep. Hillary Scholten (D-Mich.) and is titled the “Fair Prescription Pricing Act of 2026.” It is assigned to three House committees: Education & Workforce, Energy & Commerce, and Ways & Means. The article notes that a similar concept was introduced previously by Rep. Katie Porter (D-Calif.) as the “Lowest Price for Patients Act” during the 118th Congress. The multi-committee jurisdiction suggests the bill will face several policy and procedural review paths before any potential floor action.
Potential implications for employers and plan administration: The article indicates employers and benefits advisors could see advantages in limiting participants’ spending on covered drugs to amounts that do not exceed typical consumer prices. At the same time, it flags possible concerns about increased government involvement in consumer drug pricing and the operational steps required to administer a cap tied to a nationwide-average benchmark. The underlying issue highlighted is that, in some cases, paying cash for a prescription can be cheaper than using commercial coverage, which raises questions about current cost-sharing designs. If adopted, the policy could push plan sponsors and administrators to adjust point-of-sale systems and benefit designs to comply with a survey-based pricing standard.
HVBA Poll Question - Please share your insightsWhen a high-cost specialty drug or infusion claim hits your plan, what happens first? |
Our last poll results are in!
27.34%
Of the Daily Industry Report readers who participated in our last polling question, when asked: “How confident are you that your employer clients know exactly who is Medicare eligible on their group health plan?” reported “Not very confident — we suspect there are gaps but haven't evaluated them.”
26.56% of DIR respondents reported “Not confident at all — we’ve never really looked into it,” while 25% said “Very confident — we identify them and have a process for education and compliance,” and 21.10% claim “Somewhat confident — we know the numbers but don’t have a formal process.” Thank you to Aevitas for powering this polling question.
Have a poll question you’d like to suggest? Let us know!
Florida AG sues Prime Therapeutics, Express Scripts for alleged price-fixing
By Paige Minemyer – Florida Attorney General James Uthmeier is suing Express Scripts and Prime Therapeutics, alleging that a partnership between the two pharmacy benefit managers allows them to illegally fix prices. Express Scripts and Prime entered into a partnership in 2019, through which Express Scripts would provide Prime with certain services related to retail pharmacy networks and contracting with drugmakers. In the lawsuit, Uthmeier's office argues that the collaboration has led Prime to adopt far lower pharmacy reimbursement rates. Prime's reimbursement rates were about 20% higher before the partnership with Express Scripts, which can lead pharmacies to fill prescriptions at a loss, per the lawsuit. Read Full Article...
HVBA Article Summary
State antitrust allegations target a PBM partnership: Florida’s attorney general alleges the Express Scripts–Prime Therapeutics arrangement functions as an illegal price-fixing scheme. The complaint characterizes the relationship as a “horizontal” price-fixing arrangement under the Florida Antitrust Act. The state also alleges violations of the Florida Deceptive and Unfair Trade Practices Act. Florida is seeking injunctive relief, civil penalties and damages.
Core dispute centers on pharmacy reimbursement and downstream effects: The lawsuit argues that after the 2019 partnership, Prime adopted lower reimbursement rates that can push pharmacies to dispense prescriptions at a loss. In a public statement, the attorney general said this dynamic could contribute to pharmacy financial strain or closures and reduce local access to medications. The state frames the issue as particularly consequential for seniors and families relying on community pharmacies. The allegations focus on how contracting and network decisions translate into real-world availability of pharmacy services.
PBMs deny wrongdoing and say cost control benefits patients and payers: Express Scripts said it is committed to reimbursing network pharmacies fairly and will “vigorously” defend against what it called baseless allegations. Prime said the suit emphasizes pharmacy profits while overlooking the effects of higher pharmacy costs on patients, employers, health plans and taxpayers. Prime also claimed its approach lowers costs at the pharmacy counter while maintaining broad pharmacy access. The case adds to existing legal challenges to the Express Scripts–Prime partnership, including litigation filed by independent pharmacies in 2023 and another suit in July in which Express Scripts was not a named defendant.
Predictive analytics become essential as high-cost claimants surge
By Katherine Shanahan – The financial gravity of healthcare is increasingly concentrated in a small but rapidly evolving segment of patients: high-cost claimants. For employers and health plans, this group represents one of the most urgent financial risks in benefit management. New therapies, changing oncology paradigms and an expanding drug pipeline, especially for rare diseases, are reshaping the definition of high-cost members. At the same time, advances in machine learning-based risk prediction models enable organizations to be more proactive in planning benefit strategies and care coordination for these individuals. Read Full Article... (Subscription required)
HVBA Article Summary
High-Cost Claims Are Becoming Larger and Less Predictable: Healthcare spending remains highly concentrated, with roughly 1% of members accounting for about 30% of total healthcare costs. At the same time, more individuals are reaching $1 million or $2 million in annual claims, while only about 21% of high-cost claimants remain high-cost from one year to the next. This volatility makes historical claims data less reliable for forecasting future healthcare spending and identifying which members will drive costs.
Specialty Therapies and Screening Gaps Are Increasing Financial Risk: Cell and gene therapies can carry substantial costs, with CAR-T treatment episodes often exceeding $1 million and some gene therapies priced above $4 million per dose. Specialty drugs represent approximately 75% of the drug development pipeline and, despite being used by fewer than 5% of patients, already account for at least half of pharmaceutical spending. Meanwhile, 31% of adults are more than a year behind on recommended cancer screenings, potentially increasing the likelihood of later-stage diagnoses that require more intensive and costly treatment.
Predictive Analytics Are Emerging as a Tool for Prospective Cost Management: Employers and health plans are increasingly using machine learning models that combine medical, pharmacy, eligibility, demographic, and other data to identify members whose costs may rise significantly. These models are intended to help organizations anticipate when costs could occur, what conditions may drive them, and the potential financial impact before a member becomes a high-cost claimant. Such insights can support earlier care management, medication and site-of-care strategies, budgeting, stop-loss decisions, benefit design, and preventive-care initiatives.
53% of US adults feel they have no say when AI is used in care
By Cailey Gleeson – Fifty-three percent of American adults feel as though they either have “not too much” or no control over the use of artificial intelligence in their healthcare, a new survey found. Moreover, 63% of respondents polled by the Pew Research Center report that they would like more say over whether AI is used in their care. The nonprofit research firm surveyed 3,488 U.S. adults from its American Trends Panel (ATP) between June 22 and 28. Read Full Article...
HVBA Article Summary
Perceived lack of patient agency varies by demographics: The survey results indicate that perceptions of control over AI use in healthcare are not uniform across racial and ethnic groups. White adults were more likely to report having little to no say (60%) compared with Hispanic (40%), Black (43%) and Asian adults (42%) respondents. This points to differences in how empowered different groups feel in clinical settings as AI tools become more common. The findings suggest that any patient-engagement approach may need to be tailored rather than one-size-fits-all.
Uncertainty and limited understanding remain common: Nearly half of respondents (46%) said they were unsure whether AI had been used in their care at all. Separately, understanding of AI’s role was mixed: 44% reported understanding “somewhat well,” while 32% reported little to no understanding. Together, these figures suggest that AI adoption may be outpacing patient awareness and comprehension. That gap could affect trust, informed consent expectations and how patients evaluate care decisions.
Strong demand for transparency about specific AI-enabled tasks: A large majority (72%) said it is extremely or very important for providers to inform them when AI is used. Respondents most wanted disclosure when AI is applied to direct clinical or decision-influencing activities, such as analyzing scans and making diagnoses (81% each) or explaining lab results (80%). Interest in notification was also high for administrative or supportive functions like note-taking (72%), prescription refills (64%) and scheduling (56%). This pattern suggests people differentiate between higher-stakes and lower-stakes AI uses, and want communication aligned with perceived impact.
Dolly's Cancer Death; Mammogram Safety Alert; Chemo Drug Shortage Worsens
By Charles Bankhead – Representatives for entertainer Dolly Parton acknowledged that she died of cancer but did not identify the type of cancer; her sister, Stella, revealed that the singer and actress volunteered to take experimental drugsthat might help other people. ( People, Newsweek) Parton's admission that she ignored her own health problems while caring for her ailing husband highlighted a caregiver crisis in the U.S. ( CNN) A rare skin cancer that can be mistaken for eczema. ( Washington Post) The Justice Department announced that DermTech will pay $5 million to settle allegations that the company submitted false Medicare claims for unreliable skin cancer tests. The FDA issued a safety alert, notifying patients of potential quality issues with mammograms performed at the Mammography Center of Monterey in California on or after Dec. 22, 2023. Read Full Article...
HVBA Article Summary
High-profile cancer news prompted related reporting and public-health angles: The item notes that Dolly Parton’s representatives confirmed she died of cancer while not specifying the type, and it also cites reporting that she considered experimental drugs to help others. It ties her comments about prioritizing caregiving over her own health to broader concerns about caregiving strain in the U.S. The write-up frames these points as part of a round-up linking celebrity news to ongoing healthcare issues.
Multiple agencies highlighted scrutiny of testing and imaging quality: The Justice Department announcement described a $5 million settlement involving allegations of false Medicare claims tied to unreliable skin cancer tests. Separately, the FDA issued a safety alert about potential quality issues with mammograms at a specific California facility for exams performed on or after Dec. 22, 2023. Together, these updates emphasize regulatory attention on diagnostic reliability and patient notification when quality problems are suspected.
Drug supply and other cancer-related developments were grouped as quick-hit updates: The round-up reports that ASCO amplified warnings about a critical shortage of generic ifosfamide, alongside news that the FDA will temporarily allow imports from India. It also points to a range of other cancer-related items, including research updates and clinical/consumer health stories referenced from multiple outlets. The overall format is a curated list rather than a single narrative, spotlighting several simultaneous developments in oncology.
Getting the best ROI out of your benefits
By Jimmy Nesbitt – With healthcare costs heading toward a near-double-digit increase in 2027, benefit leaders are taking a hard look at every dollar they spend on the eve of open enrollment. And to truly measure a workplace perk's value, the most important question they should be asking is whether employees actually use it, said Tom Wiffler, CEO of One Pass, a fitness and wellness benefits provider. "That is where the ROI conversation needs to evolve," said Wiffler, a longtime former UnitedHealthcare executive. Read Full Article... (Subscription required)
HVBA Article Summary
Benefits Measurement Should Extend Beyond Enrollment: Enrollment can indicate initial employee interest, but it does not show whether a benefit is producing sustained value or behavioral change. Employers may gain more insight by tracking utilization frequency, engagement trends and continued participation over time. Employee feedback can also help determine whether low usage reflects limited awareness, access barriers or a lack of perceived value.
Sustained Engagement Is Presented as a Key Measure of Value: Benefits leaders are encouraged to evaluate who uses a program, how often they use it and whether engagement increases or declines over time. For fitness benefits specifically, offering multiple ways to be active may help accommodate differences in employees’ ages, abilities, schedules and interests. The interview argues that consistent engagement in movement can potentially support better health outcomes and lower healthcare utilization and costs.
Fitness Benefits Could Play a Larger Role in 2027 Benefits Strategies: The interview recommends viewing fitness programs as part of an employer’s broader health benefits strategy rather than primarily as a supplemental perk. During 2027 open enrollment, employers could focus on increasing awareness, explaining how programs work and making it easier for employees to begin and continue participating. Employers considering new or existing fitness benefits would still need to assess sustained utilization and outcomes to determine whether the programs justify their investment.
Epic MyChart Phishing Scam Hits Health Systems: What Providers Should Do
By Katie Adams – More than a dozen health systems are warning patients this week of a phishing campaign impersonating Epic‘s MyChart patient portal. The scam emails use the MyChart logo and dangle fake rewards like a “MyChart Medicare Kit” or or “senior health package” to trick patients into handing over their personal details, health records or financial information. Epic, which licenses MyChart to health systems, said the fraudulent site copies its real login page’s code and directs victims to lookalike domains — such as mychart-epic[.]com — rather than a health system’s actual Epic portal address. Read Full Article...
HVBA Article Summary
How the impersonation works: The campaign relies on brand recognition of MyChart and uses emails that mimic official portal communications. Victims are nudged toward fake incentives (such as Medicare-related “kits” or “packages”) designed to make the message feel legitimate and urgent. Epic says the fraudulent site copies the real login page’s code and sends users to lookalike domains instead of a health system’s actual portal address.
Epic’s assessment of the incident: Epic frames the activity as phishing that leverages MyChart’s familiarity, not evidence that Epic’s internal systems have been compromised. The company has documented two active variants: one that pressures patients with a fake “critical” lab result that can lead to malicious software, and another that uses a countdown-timer “survey” to collect personal and payment information. This distinction matters because the primary risk comes from credential theft and fraud via imitation, even when backend systems are intact.
What providers can do beyond technical defenses: Cybersecurity leaders argue patients should not be expected to reliably spot scams based on surface cues like grammar or logos because phishing is increasingly polished and personalized. They recommend encouraging safer patient habits—leaving unexpected messages and accessing MyChart through the official app or a provider’s known website, or contacting the provider to verify. Experts also emphasize treating patient-facing phishing as part of the broader security program, including brand-impersonation monitoring, preplanned patient communications, and coordinated roles across security, communications, and clinical teams.

GLP-1 Drugs Could Help Narrow Lifespan Gap in Serious Mental Illness
By Kristen Monaco – Starting a GLP-1 receptor agonist was associated with significantly lower risks of death and cardiovascular events in adults with serious mental illness (SMI), a target trial emulation showed. Among 195,184 propensity score-matched pairs of adults with SMI, GLP-1 drug initiators had a 24% lower 4-year mortality risk compared with SGLT2 inhibitor initiators (HR 0.76, 95% CI 0.74-0.78). Death occurred in 4.91% and 6.45% of groups, respectively, equating to an absolute risk difference of -1.54 percentage points. At year 1, all-cause mortality risk was 49% lower among GLP-1 initiators compared with SGLT2 inhibitor initiators (HR 0.51, 95% CI 0.49-0.53, P <0.001), Roger McIntyre, MD, of the University of Toronto, and colleagues reported in JAMA Psychiatry. Read Full Article...
HVBA Article Summary
Cardiovascular outcomes drove most of the observed benefit: In analyses focused on semaglutide initiators with SMI and type 2 diabetes, the reported mortality association was largely attributed to reductions in cardiovascular events. The paper lists lower risks across several endpoints, including major adverse cardiovascular events, myocardial infarction, stroke, heart failure, and coronary artery bypass grafting. The authors interpret this as suggesting a broad cardiometabolic benefit rather than a single endpoint effect.
Study design and population were based on real-world EHR data: The researchers conducted a retrospective target trial emulation using TriNetX electronic health record data through March 2026. They used a new-user, active-comparator approach and categorized 1,528,230 adults into SMI and non-SMI groups before propensity-score matching, with the SMI cohort averaging about 60.5 years old. The results were reported to persist across sensitivity analyses, though the authors noted inherent limitations of this kind of observational emulation.
Effects differed by GLP-1 agent generation and access may limit generalizability: The report states that newer agents (semaglutide and tirzepatide) were associated with reduced mortality at 4 years in people with SMI and type 2 diabetes, while older GLP-1 drugs showed no consistent survival advantage versus SGLT2 inhibitors. In exploratory 10-year analyses among people with type 2 diabetes, semaglutide was associated with lower mortality across SMI subgroups (major depressive disorder, bipolar disorder, and schizophrenia). The authors also cautioned that unmeasured factors (e.g., adherence, lifestyle, socioeconomic variables, psychiatric severity) and cost-related barriers could affect how widely these findings apply, especially given inequities in GLP-1 access for people with SMI.





